The ABBV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABBV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABBV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABBV Detailed Price Forecast - CNN Money||View ABBV Detailed Summary - Google Finance|
|View ABBV Detailed Summary - Yahoo! Finance||View ABBV Stock Research & Analysis - Zacks.com|
|View ABBV Trends & Analysis - Trade-Ideas||View ABBV Major Holders - Barrons|
|View ABBV Call Transcripts - NASDAQ||View ABBV Breaking News & Analysis - Seeking Alpha|
|View ABBV Annual Report - CompanySpotlight.com||View ABBV OTC Short Report - OTCShortReport.com|
|View ABBV Fundamentals - TradeKing||View ABBV SEC Filings - Bar Chart|
|View Historical Prices for ABBV - The WSJ||View Performance/Total Return for ABBV - Morningstar|
|View the Analyst Estimates for ABBV - MarketWatch||View the Earnings History for ABBV - CNBC|
|View the ABBV Earnings - StockMarketWatch||View ABBV Buy or Sell Recommendations - MacroAxis|
|View the ABBV Bullish Patterns - American Bulls||View ABBV Short Pain Metrics - ShortPainBot.com|
|View ABBV Stock Mentions - StockTwits||View ABBV Stock Mentions - PennyStockTweets|
|View ABBV Stock Mentions - Twitter||View ABBV Investment Forum News - Investor Hub|
|View ABBV Stock Mentions - Yahoo! Message Board||View ABBV Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABBV - SECform4.com||View Insider Transactions for ABBV - Insider Cow|
|View ABBV Major Holdings Summary - CNBC||View Insider Disclosure for ABBV - OTC Markets|
|View Insider Transactions for ABBV - Yahoo! Finance||View Institutional Holdings for ABBV - NASDAQ|
|View ABBV Stock Insight & Charts - FinViz.com||View ABBV Investment Charts - StockCharts.com|
|View ABBV Stock Overview & Charts - BarChart||View ABBV User Generated Charts - Trading View|
FDA lifts hold on one of AbbVie's trials of venetoclax
Posted on Monday June 24, 2019
The U.S. Food and Drug Administration has lifted a clinical hold on one of AbbVie's Inc's trials looking at venetoclax as a potential treatment for multiple myeloma, AbbVie said Monday. The Phase 3 trial, called CANOVA, looks at venetoclax in combination with dexamethasone as a treatment for patients with advanced multiple myleoma who also have a specific genetic abnormality. The translocation abnormality, t(11;14), is one of the most commonly tested genetic abnormalities in patients with disease. AbbVie said it had agreed to revise the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria. The drugmaker can resume enrolling patients in the CANOVA trial at sites where the protocol has been approved, but all other clinical trials of venetoclax in patients with multiple myeloma are still on hold. The FDA placed a partial hold on all of AbbVie's clinical trials of venetoclax for multiple myeloma in March. The hold came after a review of another Phase 3 trial's data showed there was a higher proportion of deaths in the treatment arm than in the control arm. Shares of AbbVie have fallen 14.6% in the year to date through Friday, while the S&P 500 has gained 17.7%.
- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria ...
Forget Bargain Hunting: Tap 5 Stocks With Rising P/E
Posted on Monday June 24, 2019
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
Posted on Friday June 21, 2019
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.